170 related articles for article (PubMed ID: 37663648)
1. Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS.
Kang SL; Woo JH; Kim NH; Kwon JY; Kim SM
Mol Ther Methods Clin Dev; 2023 Sep; 30():447-458. PubMed ID: 37663648
[TBL] [Abstract][Full Text] [Related]
2. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
3. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency.
Maliepaard M; Nibi P; Nibi G; Pasmooij AMG
Front Med (Lausanne); 2022; 9():893028. PubMed ID: 35602486
[TBL] [Abstract][Full Text] [Related]
5. Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects.
Olsen D; Jørgensen JT
Front Oncol; 2014; 4():105. PubMed ID: 24904822
[TBL] [Abstract][Full Text] [Related]
6. Companion Diagnostics: State of the Art and New Regulations.
Valla V; Alzabin S; Koukoura A; Lewis A; Nielsen AA; Vassiliadis E
Biomark Insights; 2021; 16():11772719211047763. PubMed ID: 34658618
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union.
Verbaanderd C; Trullás Jimeno A; Engelbergs J; Zander H; Reischl I; Moreno Oliver A; Vamvakas S; Vleminckx C; Bouygues C; Girard T; Day F; Frias Z
Clin Pharmacol Ther; 2023 Aug; 114(2):316-324. PubMed ID: 37132507
[TBL] [Abstract][Full Text] [Related]
8. The current landscape of the FDA approved companion diagnostics.
Jørgensen JT
Transl Oncol; 2021 Jun; 14(6):101063. PubMed ID: 33714919
[TBL] [Abstract][Full Text] [Related]
9. The Regulation of Companion Diagnostics: A Global Perspective.
Ansari M
Ther Innov Regul Sci; 2013 Jul; 47(4):405-415. PubMed ID: 30235516
[TBL] [Abstract][Full Text] [Related]
10. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
[TBL] [Abstract][Full Text] [Related]
11. Twenty-five years with companion diagnostics.
Jørgensen JT
Chin Clin Oncol; 2023 Dec; 12(6):65. PubMed ID: 37953243
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Database Approach to Identify Companion Diagnostic Testing in Clinical Trials under the New In Vitro Diagnostic Medical Devices Regulation.
Wollenhaupt C; Sudhop T; Knoess W
Diagnostics (Basel); 2023 Jun; 13(12):. PubMed ID: 37370933
[TBL] [Abstract][Full Text] [Related]
13. The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion diagnostics.
Enzmann H; Meyer R; Broich K
Biomark Med; 2016 Dec; 10(12):1261-1268. PubMed ID: 27661101
[TBL] [Abstract][Full Text] [Related]
14. ENVIRONMENTAL SCAN ON PHARMACEUTICALS REQUIRING COMPANION DIAGNOSTICS.
Cowling T; Boucher M
Int J Technol Assess Health Care; 2016 Jan; 32(5):327-336. PubMed ID: 27955717
[TBL] [Abstract][Full Text] [Related]
15. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
Front Genet; 2015; 6():357. PubMed ID: 26858745
[TBL] [Abstract][Full Text] [Related]
16. Companion and complementary diagnostics for infectious diseases.
Dailey PJ; Elbeik T; Holodniy M
Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
[TBL] [Abstract][Full Text] [Related]
17. Impact of the new European Union
Hermans AMM; Maliepaard M; Boon WPC; Pasmooij AMG
Expert Rev Mol Diagn; 2022 May; 22(5):583-590. PubMed ID: 35673983
[TBL] [Abstract][Full Text] [Related]
18. Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs.
Jørgensen JT
JCO Precis Oncol; 2022 Jun; 6():e2200100. PubMed ID: 35709402
[TBL] [Abstract][Full Text] [Related]
19. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
20. Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan.
Tanaka A; Suzuki H; Toyoshima S; Nagai N
Ther Innov Regul Sci; 2022 Jan; 56(1):85-95. PubMed ID: 34406635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
